- Report
- July 2024
- 118 Pages
Global
From €4303EUR$4,750USD£3,709GBP
- Report
- February 2024
- 113 Pages
Global
From €4303EUR$4,750USD£3,709GBP
- Report
- July 2024
- 100 Pages
Global
From €3397EUR$3,750USD£2,928GBP
- Report
- July 2024
- 150 Pages
Global
From €3397EUR$3,750USD£2,928GBP
- Report
- January 2024
- 200 Pages
Global
From €3759EUR$4,150USD£3,240GBP
- Report
- April 2023
- 150 Pages
Global
From €4394EUR$4,850USD£3,787GBP
- Report
- February 2023
- 206 Pages
Global
From €4031EUR$4,450USD£3,475GBP
- Report
- November 2023
- 110 Pages
Global
From €4077EUR$4,500USD£3,514GBP
- Report
- June 2024
- 140 Pages
Africa, Middle East
From €3505EUR$3,869USD£3,021GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3505EUR$3,869USD£3,021GBP
- Report
- June 2024
- 140 Pages
Europe
From €3505EUR$3,869USD£3,021GBP
- Report
- June 2024
- 120 Pages
North America
From €3505EUR$3,869USD£3,021GBP
- Report
- June 2023
- 263 Pages
Global
From €3261EUR$3,600USD£2,811GBP
- Drug Pipelines
- April 2023
- 34 Pages
Global
From €9054EUR$9,995USD£7,804GBP
- Drug Pipelines
- April 2023
- 34 Pages
Global
From €9054EUR$9,995USD£7,804GBP
- Report
- September 2020
- 700 Pages
Global
From €4439EUR$4,900USD£3,826GBP

Allogeneic cell therapy is a type of genomics-based therapy that uses cells from a donor to treat a patient. It is a form of immunotherapy that uses cells from a healthy donor to stimulate the patient's immune system to fight disease. Allogeneic cell therapy is used to treat a variety of conditions, including cancer, autoimmune diseases, and genetic disorders. It is also being explored as a potential treatment for neurological disorders.
Allogeneic cell therapy is a rapidly growing field, with many companies developing new treatments and technologies. Examples of companies in the allogeneic cell therapy market include Kite Pharma, Juno Therapeutics, and Bellicum Pharmaceuticals. Other companies, such as Cellectis and Fate Therapeutics, are also researching and developing allogeneic cell therapies. Show Less Read more